Stockholm, Sweden (Press Release) – CellProtect Nordic Pharma­ceu­ticals AB ('CPNP') has been notified by the Euro­pean Com­mis­sion that its cell ther­apy can­di­date CellProtect has re­ceived orphan drug desig­na­tion for the treat­ment of mul­ti­ple myeloma. CellProtect is manu­fac­tured from the patient's own blood and is the first drug can­di­date, con­sist­ing of au­tol­o­gous ex vivo activated and ex­panded nat­u­ral killer (NK) cells, which has re­ceived such desig­na­tion in Europe.

CPNP has carried out a clin­i­cal phase I/II trial in patients with mul­ti­ple myeloma where CellProtect has been studied as a supple­mental treat­ment to au­tol­o­gous stem …